Leqvio Re-Titration After Stopping: What Women Need to Know

What Happens to Your LDL-C When You Stop Inclisiran

LDL-C does not stay low after you stop inclisiran. It climbs back. Because inclisiran works by silencing the gene that codes for PCSK9 in liver cells, its effect lasts only as long as the silencing RNA remains active in hepatocytes. Once the small interfering RNA degrades, PCSK9 production resumes, and LDL receptors are cleared from the liver surface again, allowing LDL-C to rise.

In the ORION-10 and ORION-11 trials published in the New England Journal of Medicine, LDL-C reductions of around 50% from baseline were maintained at 17 months in patients who received all scheduled doses. Patients who missed injections showed loss of effect within 90 to 180 days, depending on when in the dosing cycle they stopped.

How Fast LDL-C Rebounds

There is no published, large-scale withdrawal study that tracks the precise rebound curve day by day, and that evidence gap is worth naming directly. What pharmacokinetic modeling from the ORION program suggests is that the half-life of inclisiran's LDL-C-lowering effect is roughly 6 months, which is why twice-yearly dosing maintains near-nadir suppression. Stop the drug and the effect fades at a rate roughly parallel to that 6-month biological half-life, meaning you may lose meaningful LDL-C control within 3 to 4 months of a missed dose.

Why This Matters More for Some Women

LDL-C is not static across a woman's life. It rises by an average of 10 to 15 mg/dL during the menopausal transition, a change documented in the Study of Women's Health Across the Nation (SWAN). If you stop inclisiran during perimenopause and your estrogen is simultaneously falling, you may face a double LDL-C increase. Restarting promptly is especially important in this life stage.

Women with PCOS also tend to carry higher baseline LDL-C and lower HDL-C compared to age-matched controls, which means that any gap in PCSK9 inhibition may push LDL-C into a range that accelerates cardiovascular risk faster than it would in women without the condition.

The Official Re-Titration Schedule After Stopping

The FDA-approved prescribing information for inclisiran is explicit: if a dose is missed or the drug is stopped and restarted, you repeat the loading sequence. There is no abbreviated re-start protocol. There is no half-dose bridge. You go back to the beginning.

Step-by-Step Restart Protocol

1. Day 1 (restart): 284 mg subcutaneous injection, administered by a healthcare provider in a clinical setting.
2. Month 3 (90 days later, plus or minus 2 weeks): Second 284 mg injection.
3. Every 6 months thereafter: 284 mg injection, indefinitely, as long as therapy is indicated.

The label allows a window of plus or minus 2 weeks around the Month 3 and subsequent doses. Missing that window by more than 2 weeks is what triggers the need to restart the full loading sequence again rather than simply continuing to the next scheduled dose.

Does the Dose Ever Increase?

No. There is no dose escalation in inclisiran therapy. The 284 mg dose is both the starting dose and the maintenance dose. Unlike statins, where you might step from 10 mg to 20 mg to 40 mg of rosuvastatin, inclisiran has a single approved dose. If 284 mg is not getting your LDL-C to goal, the clinical question is whether to add or intensify a statin or ezetimibe, not whether to give more inclisiran. The 2022 ACC/AHA cholesterol guideline supports this combination approach for very-high-risk patients.

What Counts as "Stopping"

Practically speaking, any gap longer than 8 months from your last scheduled dose means you have drifted outside the twice-yearly window by enough that your provider will typically restart the loading sequence. Gaps of 6 to 8 months fall into a clinical grey zone where your LDL-C level on the day of restart, your cardiovascular risk category, and your provider's judgment will guide the decision.

Why There Is No "Titration" in the Traditional Sense

The word titration implies adjusting a dose up or down based on response. Inclisiran does not work that way. The dose is fixed. What gets adjusted is the timing of re-initiation after a stop.

A useful way to think about inclisiran management is to separate two distinct clinical questions that often get conflated:

Question 1: Efficacy gap. Your LDL-C is not at goal even on inclisiran. The answer here is to review statin use, add ezetimibe, or reassess adherence. Raising the inclisiran dose is not an option.

Question 2: Dosing gap. You stopped inclisiran for any reason (pregnancy, side-effect concern, cost, procedure, provider error) and want to restart. The answer here is the full loading sequence regardless of how long you were off.

Keeping these two questions separate prevents a common clinical error: giving a patient a "bridge dose" or a "half-restart," neither of which is supported by the prescribing information or by trial data.

Reasons Women Stop Inclisiran (and What to Do About Each)

Stopping for Pregnancy Planning

Pregnancy is the most consequential reason a woman of reproductive age might stop inclisiran. The drug is classified as contraindicated in pregnancy based on animal reproduction studies showing harm, and there are no adequate human pregnancy data. The FDA label states that women of reproductive potential should use effective contraception during treatment. If you are planning a pregnancy, stop inclisiran before attempting to conceive and discuss the timing with your cardiologist and OB-GYN.

The 6-month biological effect window is relevant here. If you received a dose and then discover you are pregnant, the drug has likely already exerted most of its effect. Inform your obstetric team immediately. Do not restart until after delivery and, if breastfeeding, after weaning.

When you are ready to restart postpartum, you restart with the full loading sequence: Day 1, then Month 3, then every 6 months.

Stopping Because of a Planned Surgery

Inclisiran does not need to be stopped before surgery; the American College of Cardiology notes no interaction with anesthetic agents or surgical bleeding risk specific to PCSK9 inhibitors. However, if a dose falls due during a hospitalization and is skipped, restart the loading sequence if the gap exceeds the allowable window.

Stopping Because of Cost or Access Issues

Insurance coverage for inclisiran varies, and prior authorization denials are common. If cost caused your gap, your provider can submit a new prior authorization upon restart; you should not attempt to resume on a maintenance schedule if you have been off for more than 8 months, as your LDL-C will have rebounded and the clinical rationale for the loading sequence will be the same as for a new patient.

Stopping Because of Injection-Site Reactions

Injection-site adverse events occurred in approximately 8.2% of patients in the pooled ORION-10 and ORION-11 analysis, most of which were mild (pain, erythema, bruising). These reactions are transient and generally resolve within 2 weeks. Switching injection sites among the abdomen, upper arm, and thigh may reduce recurrence. If you stopped for this reason and want to restart, you restart the loading sequence and discuss site rotation technique with your provider before the injection.

Pregnancy, Lactation, and Contraception

This section is required for every drug article on WomanRx because the consequences of missing this information are serious.

Pregnancy

Inclisiran is contraindicated in pregnancy. Animal studies with inclisiran at exposures several times the human dose showed developmental toxicity. There are no controlled human pregnancy trials, and the FDA label categorizes the drug as contraindicated based on this animal evidence and the biological plausibility that PCSK9 inhibition could affect fetal lipid metabolism, which is required for normal neurological development.

If you are pregnant, do not receive inclisiran. If you received a dose before you knew you were pregnant, report the exposure to the Novartis pregnancy pharmacovigilance registry (available through your prescriber) and notify your obstetric team.

After delivery, restart only when you are no longer pregnant and, if applicable, no longer breastfeeding.

Lactation

It is not known whether inclisiran or its metabolites are excreted in human breast milk. The molecular weight and lipid-nanoparticle delivery mechanism make systemic transfer to milk biologically plausible. Given the potential for adverse effects in a breastfeeding infant, the FDA label recommends against use during breastfeeding. The decision to breastfeed or use inclisiran is one to make with your cardiologist and OB-GYN, weighing maternal cardiovascular risk against the desire to breastfeed.

Contraception Requirements

Women of reproductive age receiving inclisiran should use effective contraception throughout treatment. The label does not specify a required washout period before attempting conception after stopping, but given the 6-month biological half-life of the LDL-lowering effect, a conservative approach is to allow one full dosing cycle (6 months) to elapse after the last injection before trying to conceive. Discuss this timeline with your reproductive endocrinologist or OB-GYN.

Life-Stage Guide to Re-Titration Timing

Reproductive Years (Ages 18 to 40)

Women in this group are most likely to stop inclisiran for pregnancy or contraceptive changes. Restart with the full loading sequence after delivery and weaning. Coordinate restart timing with your postpartum cardiology follow-up, typically at 6 to 12 weeks postpartum.

Women with familial hypercholesterolemia (FH) in this age group face a specific challenge: LDL-C in FH is elevated from birth, and even a 3-to-6-month gap significantly increases cumulative LDL-C exposure. A 2023 analysis in the European Heart Journal estimated that each 1 mmol/L (roughly 39 mg/dL) year of LDL-C exposure increases cardiovascular event risk by approximately 22%. Minimizing gaps in inclisiran therapy matters especially in FH.

Perimenopause (Typically Ages 45 to 55)

Perimenopause is often the life stage when cardiovascular risk accelerates fastest in women, partly because declining estrogen removes its protective effect on LDL receptor activity. The Menopause Society's 2023 position statement acknowledges this cardiovascular risk inflection and supports lipid optimization during the menopausal transition.

If you stopped inclisiran during perimenopause for any reason, prioritize restarting promptly. Discuss whether menopausal hormone therapy (MHT) and inclisiran can run concurrently with your provider. The two are not contraindicated together, and MHT with estrogen may itself modestly lower LDL-C, though the magnitude is smaller than inclisiran's effect.

Post-Menopause (Ages 55 and Beyond)

Post-menopausal women carry the highest absolute cardiovascular risk of any female life stage. LDL-C reduction in absolute terms saves more lives in high-risk post-menopausal women than in any other female group. A gap in therapy here is clinically consequential. Restart the loading sequence without delay.

Women who have had premature ovarian insufficiency (POI) face an accelerated cardiovascular risk timeline and may need inclisiran therapy earlier and with fewer allowable gaps than the general population.

Monitoring After Re-Titration

After restarting the loading sequence, check a fasting lipid panel at the following points:

• 4 to 6 weeks after the Day-1 restart dose: This gives your provider a sense of whether LDL-C is responding. The nadir of effect occurs at approximately 30 days post-injection.
• Just before the Month-3 second loading dose: Compare to the 4-to-6-week value; LDL-C may rise slightly in the interval between doses before the second injection drives it lower again.
• 3 to 6 months after the Month-3 dose: This is the approximate steady-state check under a full every-6-month schedule.

If LDL-C is not at goal after two full loading doses, revisit statin intensity, check for adherence issues, and consider whether ezetimibe should be added. Do not interpret a suboptimal LDL-C response as a reason to give inclisiran more frequently. The ORION-1 dose-finding trial tested several inclisiran doses and confirmed that 300 mg (the precursor formulation to 284 mg of the sodium salt) given twice yearly was the optimal benefit-to-safety balance; more frequent dosing was not more effective.

Who This Approach Is Right For (and Who Should Pause)

Women Who Should Restart Inclisiran Promptly

• Post-menopausal women with atherosclerotic cardiovascular disease (ASCVD) who stopped for logistical reasons.
• Women with heterozygous or homozygous familial hypercholesterolemia who have been off for any duration.
• Women with PCOS and LDL-C above goal despite maximally tolerated statin therapy, though evidence for inclisiran specifically in PCOS is extrapolated from general high-risk trials rather than PCOS-specific data. That evidence gap is worth discussing with your provider.
• Women who have had a myocardial infarction or stroke and are in secondary prevention.

Women Who Should Not Restart Without Further Evaluation

• Women who are pregnant or trying to conceive within the next 6 months.
• Women who are actively breastfeeding.
• Women who stopped because of a serious liver event (inclisiran is hepatically metabolized and caution is warranted in significant hepatic impairment, per the label).
• Women whose LDL-C is currently at goal on statin plus ezetimibe alone and who stopped inclisiran without a clear reason to restart it beyond goal attainment.

Drug Interactions and Female-Specific Pharmacokinetics

Inclisiran has a favorable drug-interaction profile because it is not metabolized by cytochrome P450 enzymes. This matters for women who take hormonal contraceptives, which often interact with CYP3A4-dependent drugs. Inclisiran does not interact with combined oral contraceptives, progestin-only pills, hormonal IUDs, or menopausal hormone therapy at the pharmacokinetic level.

Sex-specific pharmacokinetic data from the ORION trials showed that women had modestly higher peak plasma concentrations of inclisiran than men, attributed to lower body weight and volume of distribution on average. Despite this, the 284 mg fixed dose was not adjusted by sex in the trials, and no sex-stratified dose recommendation exists in the label. The LDL-C lowering efficacy was comparable between women and men in the ORION-10 and ORION-11 pooled analyses.

Women represented approximately 30% of the ORION-10 and ORION-11 trial populations, a number that is better than many older cardiovascular trials but still leaves a meaningful evidence gap for sex-specific outcomes. The LDL-C efficacy data in women are reassuring, but long-term cardiovascular event data specifically in women on inclisiran remain limited. That is the honest picture.

Practical Questions Before Your Restart Appointment

Bring this list to your provider when you schedule a restart injection:

• How long have I actually been off inclisiran (exact date of last injection)?
• What is my current LDL-C on whatever therapy I am using now?
• Am I pregnant, planning pregnancy, or breastfeeding?
• Is my statin and ezetimibe regimen optimized before adding inclisiran back?
• Does my insurance require a new prior authorization for a restart?
• Where will my injection be administered (inclisiran must be given by a healthcare professional; self-injection is not approved)?

Because inclisiran must be administered in a clinical setting, your re-titration is not something you can manage at home the way you might adjust an oral medication. Each injection requires a scheduled appointment. Build that into your planning, particularly if you have a busy travel or work schedule that caused the original gap.

Your LDL-C is not waiting. The restart loading sequence takes 3 months to complete. Begin as soon as your clinical situation allows.